• Loading stock data…

Report from Extraordinary General Meeting in LIDDS

Last Updated on March 11, 2022 by GlobeNewsWire

UPPSALA, SWEDEN – LIDDS AB (publ)’s (“LIDDS” or the “Company”) Extraordinary General Meeting was held 11 March 2022 in the Company’s premises in Uppsala. The Extraordinary General Meeting resolved as set out below.

Authorisation to issue convertibles
The Extraordinary General Meeting resolved in accordance with the Board of Directors’ proposal to authorise the Board of Directors to, within the scope of the articles of association, with deviation from the shareholders’ pre-emption rights, on one or several occasions during the period until the next Annual General Meeting, resolve to issue convertibles in the Company. Such issue may only be made in accordance with the financing agreement that the Company entered into with Nice & Green S.A. on 22 February 2022 and on the terms further described in the Board of Directors’ proposal to resolution.

The purpose of the authorisation and the reason for deviation from the shareholders’ pre-emption rights is for the Company to be able to draw tranches under the financing agreement and thereby being able to meet such need for flexible financing that the Company’s product development operations require.

Minutes from the meeting and complete resolutions
The minutes from the Extraordinary General Meeting will be made available at the Company’s head office and on the Company’s website, http://www.liddspharma.com.

For further information, please contact

Nina Herne, CEO
Phone: +46 (0)70 714 74 57,
E-mail: nina.herne@liddspharma.com

Jenni Bjornulfson, CFO
Phone: +46 (0)708 55 38 05
E-mail: jenni.bjornulfson@liddspharma.com

LIDDS Certified Adviser is Redeye AB.
Tel: [+46] 8 121 576 90
E-mail: certifiedadviser@redeye.se

The information was submitted for publication, through the agency of the aforementioned contact person, on March 11, 2022 at 13.00 CET.

LIDDS in brief:
LIDDS is a Swedish drug delivery company based on the proprietary technology NanoZolid(R). With NanoZolid(R), LIDDS can formulate drugs for local administration, with a maintained and controlled release for up to six months. The technology is versatile, can be used across different drug classes and solve problems within many indication areas. LIDDS offers the NanoZolid(R) technology to partners and has developed its own pipeline focused on oncology, where the technology enables delivery of a local and high drug dose, administered over time with very limited side effects. LIDDS has a broad pipeline with several projects in clinical development, both in early and late-stage clinical phase, and projects about to enter clinical development. The company is listed on Nasdaq First North Growth market.




Print Friendly, PDF & Email
Spread the word

Reader Interactions

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: